Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

PHASE2CompletedINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

October 16, 2018

Study Completion Date

February 4, 2019

Conditions
Chronic Migraine or Episodic Migraine
Interventions
DRUG

Placebo

Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.

DRUG

AMG 301

AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.

Trial Locations (49)

1090

Research Site, Vienna

2600

Research Site, Glostrup Municipality

6020

Research Site, Innsbruck

8000

Research Site, Aarhus

8800

Research Site, Viborg

9020

Research Site, Klagenfurt

10117

Research Site, Berlin

10435

Research Site, Berlin

11803

Research Site, Plainview

20100

Research Site, Turku

20251

Research Site, Hamburg

24149

Research Site, Kiel

27405

Research Site, Greensboro

32216

Research Site, Jacksonville

32801

Research Site, Orlando

33407

Research Site, West Palm Beach

37203

Research Site, Nashville

38119

Research Site, Memphis

40100

Research Site, Jyväskylä

44195

Research Site, Cleveland

48104

Research Site, Ann Arbor

63141

Research Site, St Louis

63303

Research Site, City of Saint Peters

75214

Research Site, Dallas

78681

Research Site, Round Rock

78731

Research Site, Austin

80301

Research Site, Boulder

84109

Research Site, Salt Lake City

90220

Research Site, Oulu

90404

Research Site, Santa Monica

90806

Research Site, Long Beach

06118

Research Site, East Hartford

06905

Research Site, Stamford

01605

Research Site, Worcester

T3M 1M4

Research Site, Calgary

V3Z 2N6

Research Site, Surrey

L3R 9X3

Research Site, Markham

M4S 1Y2

Research Site, Toronto

G6W 0M6

Research Site, Lévis

H2W 1V1

Research Site, Montreal

616 00

Research Site, Brno

120 00

Research Site, Prague

140 59

Research Site, Prague

750 02

Research Site, Přerov

00100

Research Site, Helsinki

00930

Research Site, Helsinki

04107

Research Site, Leipzig

112 45

Research Site, Stockholm

114 33

Research Site, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03238781 - Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention | Biotech Hunter | Biotech Hunter